The treatment of migraine has been bedevilled by the multitude of drugs which improve the condition and the lack of any which cure it. This situation indicates the considerable knowledge acquired about factors contributing to the migraine attack, without the formation of any firm concept of the underlying disturbance.
It is now well accepted that the extracranial blood vessels undergo phases of constriction, dilatation, and possibly fixation of the vessel wall by oedema as a part of the migraine attack (Tunis and Wolff, 1952; Lund, 1957) . The most likely explanation of transient paraesthesiae, aphasia, or hemiparesis in migraine is constriction of the middle cerebral artery and its branches. Fortification spectra (turret-shaped or zig-zag hallucinations of light and colour) are probably the result of changes in the posterior cerebral artery supplying the visual cortex, and slow waves may appear in the E.E.G. tracing from the appropriate posterior quadrant. Unformed flashes of light indicate spasm of the ophthalmic artery if they are restricted to the field of one eye, or of the posterior cerebral artery if they occupy homonymous half-fields. Constriction of the basilar artery may contribute brain-stem symptoms of tinnitus, vertigo, dysarthria, dyscoordination, ataxia, or loss of consciousness (Bickerstaff, 1961a, b) . Fluid retention is common at the time of the migraine headache (Schottstaedt and Wolff, 1955) , but prevention of fluid accumulation by diuretics does not influence the onset of the headache (Ostfeld, Reis, Goodell, and Wolff, 1955) . The pain of the headache is consequent upon dilatation of extracranial vessels and the presence of chemical substances around the vessel, producing a sterile inflammatory reaction (Chapman, Ramos, Goodell, Silverman, and Wolff, 1960) . Nausea and vomiting are the usual accompaniments of migraine and diarrhoea is not uncommon.
The search for a humoral agent which could constrict and dilate blood vessels, produce oliguria, and stimulate the gut led to consideration of 'Sandoz research fellow in neurology.
5-hydroxytryptamine (serotonin) as a possible mediator of the migraine syndrome. Sicuteri, Testi, and Anselmi (1961) showed that 24-hour excretion of urinary hydroxy indoles (which include 5-hydroxyindoleacetic acid, 5HIAA, the chief breakdown product of serotonin) was increased during the migraine attack. Preliminary observations of our own have confirmed that 5HIAA excretion increases with the onset of migraine and that this change precedes the onset of vomiting. Ostfeld, Chapman, Goodell, and Wolff (1957) claimed that a headache similar to migraine could be produced by periarterial injection of serotonin, but this has since been denied by Kimball, Friedman, and Vallejo (1960) . These authors could not find any significant change in plasma serotonin levels during the migraine attack, but showed that the headache could be relieved by the injection of 5 mg. of serotonin intravenously. The concentration of serotonin in the cerebrospinal fluid is not altered in migraine (Southren and Christoff, 1962) . It is known that the administration of reserpine will denude blood platelets of their serotonin content (Haverback, Dutcher, Shore, Tomich, Terry, and Brodie, 1957 ) and yet the long-term administration of reserpine has no significant effect on the frequency of migraine attacks (Friedman, 1955) . However, the injection of 2 5 mg. reserpine will precipitate a migraine-type headache in a susceptible subject, which can be relieved by the injection of 5-hydroxytryptophane, the precursor of serotonin (Kimball et al., 1960) .
In spite of the lack of definite evidence implicating serotonin in the causation of migraine, a serotonin antagonist, methysergide, has recently been used for the prevention of the migraine attack with considerable success (Sicuteri, 1959; Dalsgaard-Nielsen, 1960; Heyck, 1960; Harris, 1961; Friedman and Losin, 1961; Hale and Reed, 1962; Rooke, Rushton, and Peters, 1962; Ekbom, 1962; Friedman and Elkind, 1963; Graham, 1964 daily. The 11 patients who relapsed after some months on methysergide therapy had never been completely free of headache, i.e., no patient who became headache-free during the first month of methysergide therapy has relapsed. Forty-six patients from the 'substantially improved' and 'no change' groups were at some time in the course of treatment given a vasodilator drug in addition to their maintenance dose of methysergide. The drugs used were nicotinic acid 50-100 mg. t.d.s., Ronicol 25-50 mg. t.d.s., and Hydergine 0-5 mg. t.d.s., the patient adjusting the dose to produce facial flushing. It was noted that 17 patients had significantly fewer headaches than on methysergide alone and 10 of these 17 patients became free of headache. Twenty-eight patients were unchanged by the addition of vasodilator substances, and one was made worse. In contrast to the result of combined therapy, of 13 patients given vasodilators alone, none was improved and five became worse. SIDE-EFFECTS Side-effects of methysergide were experienced by 140 patients (45%) of the 308 presenting for review. The majority of these were mild or transient, and comprised the symptoms outlined by Lance et al. (1963) , who found that 12% of patients given placebo tablets complained of similar mild side-effects. In 32 of our patients (10%) the side-effects were of sufficient severity to warrant the discontinuation of methysergide. Thirty-one of these patients were women. The main symptom responsible for each patient ceasing treatment is listed in Table 111 .
In all but six patients the side-effects listed above developed on the first or second day of methysergide therapy, often after only one or two tablets. Two patients developed intermittent claudication after six and 11 months respectively. A 65-year-old woman developed angina pectoris after six months' therapy with methysergide, which is classified as a onth period is significantly greater than They found that 141 'severe' headaches were expatients responding to cyproheptadine perienced by 34 patients while on placebo and 103 )1), the 34% of patients responding to while on methysergide, the trial period being six = < 0-001), and the 20% response to weeks with a 'cross-over' design. This reduction = < 0-001).
appears unimpressive, but could represent eight of their 34 patients becoming headache free and a further nine being 'half improved', a yield of 50% improvement, as their patients suffered severe headaches at least once a fortnight. Southwell et al. (1964) commented that the effect of methysergide may have continued into the second six-week period, when the patient was taking placebo. We have noted the reverse situation on occasions when patients who have been well-controlled with methysergide suddenly stop medication and experience a 'rebound' recurrence of headache at a frequency greater than that before treatment was started. Graham (1964) also commented on this. Side-effects were frequent. Many of the transient disturbances such as nausea became less of a problem when patients started with one tablet (1 mg.) after meals, and then increased to 2 mg. three times daily after a few days. When the patient was established on the full dosage, the timing was altered so that the first dose was taken on waking and the last on retiring.
The most troublesome side-effects were those presumably caused by vasoconstriction. Methysergide is said not to alter the peripheral circulation in animals and does not constrict the conjunctival blood vessels in man, although it potentiates the effect of norepinephrine (Dalessio, Camp, GoodelL and Wolff, 1961) .
Definite evidence of constriction of a major artery was obtained in one patient who was taking methysergide on our advice while living in New Guinea, but who was not under our direct care. This patient had been taking 6 mg. methysergide daily for four months when she noticed pain in the right arm immediately before departing by air for London. On arrival in London she was admitted to University College Hospital under the care of Professor M. Rosenheim. Pulses in the right arm below the axillary artery were impalpable. Surgical exploration, performed after angiographic confirmation of an obstructed brachial artery, showed that the vessel was reddened and in spasm. She made a complete recovery after cessation of methysergide.
Fifteen of our patients had to cease treatment because of symptoms suggesting vasoconstriction, and 19 patients experienced a lesser degree of pain in the limbs, often after taking only one or two tablets. The addition of a vasodilator drug relieved the symptom in some instances, without nullifying the beneficial effect of methysergide on the patients' headache. Indeed a further increment of improvement was observed in 17 of 46 patients treated with a combination of vasodilator drug and methysergide. The only episode in our series which was alarming was the experience of a woman, aged 21 years, who developed tightness of the chest with aching in the left arm, dyspnoea, and palpitations after taking one tablet. This was almost certainly caused by coronary vasoconstriction, which fortunately appears to be a rare reaction to the drug. Graham (1964) has reported two patients with 'retroperitoneal fibrosis' following phlebitis of the legs. He informed us by letter that these patients presented with ureteric obstruction.
We have advised female patients to cease methysergide should they become pregnant, because the majority of women have a remission of migraine during pregnancy, and because methysergide is chemically very closely related to the ergot alkaloids which have recognized oxytocic effects. Graham (1960) mentioned that one patient, who was five and one half months pregnant, began a threatened abortion 12 hours after taking the second dose of 2 mg. of methysergide. One of our patients did not realize that she was pregnant for some months, and so continued treatment with methysergide for the first three and a half months of her pregnancy. She stated it was the best pregnancy of her last three, as one had been associated with a number of threatened miscarriages, and the second terminated in a miscarriage. She gave birth to a healthy girl who is now 4 months old.
It is doubtful whether weight gain should be regarded as a side-effect of methysergide. It may well be a non-specific response to a patient's improved health, since 16 ofthe 18 patients experiencing weight gain were improved. We have noticed a comparable increase in weight in patients whose headaches have been relieved by drugs other than methysergide. The weight gain usually ceased after two months.
The mechanism of action of methysergide is at present unknown. Dalessio et al. (1961) have suggested that methysergide exerts its effect in two ways: centrally by modulating vasomotor functions, and peripherally by potentiating the vasoconstrictor responses of the cranial blood vessels to catecholamines. Dalessio (1962) has shown that methysergide inhibits a number of vasomotor reflexes, e.g., the pressor response to unilateral carotid occlusion and the depressor responses to stimulation of the central end of the cut vagus nerve. Elkind, Friedman, and Grossman (1964) , using radioactive sodium to measure the effective skin blood flow, reported that there was no consistent change in skin blood flow after parenteral administration of methysergide, although intravenous noradrenaline and ergotamine tartrate reduced skin blood flow in most patients because of their vasoconstrictor action.
Many of our patients who have become free of headache on methysergide have mentioned that they feel that headaches are present in the background at times but do not develop or cause pain. It is possible that they are attempting to describe the sensation of vascular dilatation divorced from its usual painful accompaniment. Some of our patients who in the past had noticed unilateral dilatation of the temporal vessels accompanying migraine, still noticed this in the absence of headache on occasion while taking methysergide. Two patients whose headache was precipitated by exertion found that they were still aware of pulsation of the scalp vessels on exercise but that their customary headache did not follow. One patient who suffered severe second daily right hemicrania which was accompanied by a right-sided Homer's syndrome in a manner similar to Horton's 'histaminic cephalalgia', was admitted to hospital. The patient became free of headache when methysergide was administered, but a transient Horner's syndrome was observed on several occasions during her stay in hospital.
These observations suggest that methysergide is either reducing the degree of vascular dilatation to the point where it is no longer painful, or blocking the action of some pain-producing substance peripherally. There is no indication that methysergide depends for its action on sustaining constriction of cranial vessels; in fact vasodilator drugs appear to enhance the efficacy of methysergide rather than reduce it. Most of the patients who suffered vasoconstriction as a side-effect were relieved of migraine, although four such patients continued to have attacks at their previous frequency. Vasoconstrictor symptoms were often asymmetrical, often occurred after small doses of methysergide, and affected a comparatively small number of patients in the series, making it unlikely that this effect is the property of methysergide essential for the control of migraine.
Methysergide has proved of great benefit in reducing the frequency and severity of migraine attacks. Because of the nature of side-effects, it is advisable for any patient to remain under medical supervision for the duration of treatment, which will probably have to be continued as long as the tendency to migraine persists. Bellergal and cyproheptadine have fewer and milder side-effects than methysergide, and are therefore worth a trial first so that metbysergide may be reserved for unresponsive patients.
SUMMARY
A lysergic acid derivative, methysergide (Deseril), has been subjected to clinical trial in a series of 320 patients suffering one or more severe migraine attacks each month. Sixty-three patients (20%) became virtually free of headache, and a further 117 (36%) were substantially improved over a follow up period extending to 18 months. Results were better in patients experiencing three or more headaches each month.
Side-effects were experienced by 45 % of patients, but these were mostly mild and/or transient. However, methysergide had to be discontinued in 32 patients (10%), 17 of whom experienced vasoconstrictive phenomena. Thirty-one of these patients were women.
Methysergide proved more effective in the prophylaxis of migraine than another serotonin antagonist, cyproheptadine, and the long-used preparation Bellergal.
It is concluded that methysergide is both effective and useful in the prevention of frequent migraine attacks. The importance of the patient remaining under strict medical supervision is emphasized.
